Volgen
David W. Cescon
David W. Cescon
Medical Oncologist and Clinician Scientist, Princess Margaret Cancer Centre, University of Toronto
Geverifieerd e-mailadres voor uhn.ca
Titel
Geciteerd door
Geciteerd door
Jaar
Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
CM Booth, LM Matukas, GA Tomlinson, AR Rachlis, DB Rose, HA Dwosh, ...
Jama 289 (21), 2801-2809, 2003
18762003
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 …
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ...
The Lancet 396 (10265), 1817-1828, 2020
11882020
Functional variants of OCTN cation transporter genes are associated with Crohn disease
VD Peltekova, RF Wintle, LA Rubin, CI Amos, Q Huang, X Gu, B Newman, ...
Nature genetics 36 (5), 471-475, 2004
9812004
Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression
IS Harris, AE Treloar, S Inoue, M Sasaki, C Gorrini, KC Lee, KY Yung, ...
Cancer cell 27 (2), 211-222, 2015
9022015
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Annals of Oncology 30 (3), 397-404, 2019
6832019
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ...
Annals of Oncology 30 (3), 405-411, 2019
5302019
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
H Xu, M Di Antonio, S McKinney, V Mathew, B Ho, NJ O’Neil, ND Santos, ...
Nature communications 8 (1), 14432, 2017
4652017
Circulating tumor DNA and liquid biopsy in oncology
DW Cescon, SV Bratman, SM Chan, LL Siu
Nature Cancer 1 (3), 276-290, 2020
3632020
Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer
J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ...
New England Journal of Medicine 387 (3), 217-226, 2022
3392022
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival
C Gorrini, PS Baniasadi, IS Harris, J Silvester, S Inoue, B Snow, PA Joshi, ...
Journal of Experimental Medicine 210 (8), 1529-1544, 2013
3002013
Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2
S Inoue, WY Li, A Tseng, I Beerman, AJ Elia, SC Bendall, F Lemonnier, ...
Cancer cell 30 (2), 337-348, 2016
2052016
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo+ chemotherapy for previously untreated locally recurrent inoperable or …
J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ...
Journal of Clinical Oncology 38 (15_suppl), 1000-1000, 2020
1962020
Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086
S Loi, S Adams, P Schmid, J Cortés, DW Cescon, EP Winer, ...
Annals of Oncology 28, v608, 2017
1892017
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent
JM Mason, DCC Lin, X Wei, Y Che, Y Yao, R Kiarash, DW Cescon, ...
Cancer cell 26 (2), 163-176, 2014
1802014
Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Journal of Clinical Oncology 35 (15_suppl), 1008-1008, 2017
1692017
Evolution of the randomized controlled trial in oncology over three decades
CM Booth, DW Cescon, L Wang, IF Tannock, MK Krzyzanowska
Journal of Clinical Oncology 26 (33), 5458, 2008
1652008
If we build it they will come: targeting the immune response to breast cancer
ME Gatti-Mays, JM Balko, SR Gameiro, HD Bear, S Prabhakaran, J Fukui, ...
NPJ breast cancer 5 (1), 37, 2019
1642019
Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis
H Goldvaser, TA Barnes, B Šeruga, DW Cescon, A Ocaña, D Ribnikar, ...
JNCI: Journal of the National Cancer Institute 110 (1), 31-39, 2018
1632018
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Q Wu, W Ba-Alawi, G Deblois, J Cruickshank, S Duan, E Lima-Fernandes, ...
Nature communications 11 (1), 4205, 2020
1622020
A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn’s disease
B Newman, X Gu, R Wintle, D Cescon, M Yazdanpanah, X Liu, ...
Gastroenterology 128 (2), 260-269, 2005
1562005
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20